US2013272990A1PendingUtilityA1

Ion binding polymers and uses thereof

65
Assignee: RELYPSA INCPriority: Mar 30, 2004Filed: Oct 5, 2012Published: Oct 17, 2013
Est. expiryMar 30, 2024(expired)· nominal 20-yr term from priority
Inventors:Dominique CharmotHan-Ting ChangMingjun LiuGerrit Klaerner
A61P 39/02A61P 9/04A61P 39/04A61P 9/12A61P 7/00A61P 7/10A61P 9/00A61P 7/08A61P 3/12A61P 3/04A61P 3/00A61P 13/12A61P 1/16A61K 9/1635A61K 45/06A61K 9/5031A61K 31/80A61K 31/78A61K 9/14A61K 9/5026A61K 31/74A61K 31/795A61K 31/785C08F 128/02C08F 120/06A61K 9/28
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising a potassium binding polymer and a pharmaceutically acceptable excipient, the potassium binding polymer being a crosslinked cation exchange polymer comprising a Ca 2+  cationic counterion and acid groups in their acid or salt form, the acid groups having an electron-withdrawing substituent attached to a carbon atom alpha or beta to the acid group. 
     
     
         2 . The pharmaceutical composition of  claim 1  wherein the electron-withdrawing substituent is selected from the group consisting of a hydroxyl group, an ether group, an ester group, and a halide atom. 
     
     
         3 . The pharmaceutical composition of  claim 1  wherein the acid group is carboxylic. 
     
     
         4 . The pharmaceutical composition of  claim 1  wherein the acid group is phosphonic. 
     
     
         5 . The pharmaceutical composition of  claim 3  wherein the potassium-binding polymer comprises a crosslinked carboxylic polymer having fluoride attached to the carbon atom alpha to the carboxylic acid group. 
     
     
         6 . The pharmaceutical composition of  claim 1  wherein the potassium binding polymer has a swelling ratio of less than about 5. 
     
     
         7 . The pharmaceutical composition of  claim 1  wherein the potassium binding polymer has a swelling ratio of less than about 3. 
     
     
         8 . The pharmaceutical composition of  claim 1  wherein the ionization of the acid groups is greater than about 75% at the physiological pH in the colon. 
     
     
         9 . The pharmaceutical composition of  claim 1  wherein the potassium-binding polymer is in a bead form. 
     
     
         10 . The pharmaceutical composition of  claim 1  in the form of a chewable tablet. 
     
     
         11 . A pharmaceutical composition comprising a potassium binding polymer and a pharmaceutically acceptable excipient, the potassium binding polymer being a crosslinked alpha-fluoroacrylic acid polymer comprising a Ca 2+  cationic counterion. 
     
     
         12 . The pharmaceutical composition of  claim 11  wherein the potassium binding polymer has a swelling ratio of less than about 5. 
     
     
         13 . The pharmaceutical composition of  claim 11  wherein the potassium binding polymer has a swelling ratio of less than about 3. 
     
     
         14 . The pharmaceutical composition of  claim 11  wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinylbenzene, ethylene bisacrylamide, N,N′-bis(vinylsulfonylacetyl)ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N′-methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof. 
     
     
         15 . The pharmaceutical composition of  claim 11  wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene. 
     
     
         16 . The pharmaceutical composition of  claim 11  in the form of a chewable tablet. 
     
     
         17 . The pharmaceutical composition of  claim 11  wherein the potassium-binding polymer is in a bead form. 
     
     
         18 . A pharmaceutical composition comprising a potassium binding polymer and a pharmaceutically acceptable excipient, the potassium binding polymer being a crosslinked cation exchange polymer comprising acid groups in their acid or salt form, the acid groups selected from sulfonic, sulfuric, phosphonic, phosphoric, and sulfamate and having an electron-withdrawing substituent attached to a carbon atom alpha or beta to the acid group. 
     
     
         19 . The pharmaceutical composition of  claim 18  wherein the electron-withdrawing substituent is selected from the group consisting of a hydroxyl group, an ether group, an ester group, and a halide atom. 
     
     
         20 . The pharmaceutical composition of  claim 18  wherein the acid group is phosphoric. 
     
     
         21 . The pharmaceutical composition of  claim 18  wherein the acid group is phosphonic. 
     
     
         22 . The pharmaceutical composition of  claim 18  wherein the electron withdrawing group is fluoride. 
     
     
         23 . The pharmaceutical composition of  claim 18  wherein the potassium binding polymer has a swelling ratio of less than about 5. 
     
     
         24 . The pharmaceutical composition of  claim 18  wherein the potassium binding polymer has a swelling ratio of less than about 3. 
     
     
         25 . The pharmaceutical composition of  claim 18  wherein the potassium-binding polymer is in a bead form. 
     
     
         26 . The pharmaceutical composition of  claim 18  in the form of a chewable tablet.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.